Claims for Patent: 8,859,542

Summary for Patent: 8,859,542

Title:	Triazine compounds as PI3 kinase and mTOR inhibitors
Abstract:	Compounds of formula I ##STR00001## wherein: R.sup.1 is ##STR00002## and R.sup.2, R.sup.4, and R.sup.6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Inventor(s):	Venkatesan; Aranapakam Mudumbai (Rego Park, NY), Chen; Zecheng (New City, NY), Dehnhardt; Christoph Martin (New York, NY), Dos Santos; Osvaldo (Astoria, NY), Delos Santos; Efren Guillermo (Nanuet, NY), Zask; Arie (New York, NY), Verheijen; Jeroen Cunera (Highland Mills, NY), Kaplan; Joshua Aaron (Nyack, NY), Richard; David James (Warwick, NY), Ayral-Kaloustian; Semiramis (Tarrytown, NY), Mansour; Tarek Suhayl (New City, NY), Gopalsamy; Ariamala (Mahwah, NJ), Curran; Kevin Joseph (Congers, NY), Shi; Mengxiao (Eastchester, NY)
Assignee:	Wyeth LLC (New York, NY)
Application Number:	14/259,414
Patent Claims:	1. A method of treating a cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain cancer, soft-tissue sarcoma, and bone sarcoma, comprising concurrently administering to a mammal in need thereof a first compound of Formula I: ##STR00046## wherein: R.sup.1 is ##STR00047## or ##STR00048## wherein: R.sup.6, R.sup.7, R.sup.8, R.sup.9 are each independently selected from the group consisting of a hydrogen atom, and a C.sub.1-C.sub.6alkyl optionally substituted with C.sub.2-C.sub.6alkenyl, C.sub.4-C.sub.6alkadienyl, C.sub.2-C.sub.6alkynyl or C.sub.4-C.sub.6alkadiynyl; or one of R.sup.6 and R.sup.7 or R.sup.8 and R.sup.9, together with the carbon atoms to which they are attached form an optionally substituted 5-8 membered saturated or unsaturated ring containing 0, 1 or 2 atoms independently selected from O, NH and S; the dashed line - - - represents an optional second bond; R.sup.2 is optionally substituted C.sub.6-C.sub.14aryl-NH--COR.sup.3, optionally substituted C.sub.1-C.sub.9heteroaryl-NH-COR.sup.3, --CH.dbd.CH--C.sub.6-C.sub.10aryl-NH--COR.sup.3 or --CH.dbd.CH--C.sub.1-C.sub.9heteroaryl-NH--COR.sup.3; R.sup.3 is OR.sup.5, NR.sup.5R.sup.5 or NHR.sup.5; R.sup.5 is independently selected from the group consisting of C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6alkenyl, C.sub.3-C.sub.6alkynyl, optionally substituted C.sub.6-C.sub.10aryl, C.sub.1-C.sub.6haloalkyl, optionally substituted C.sub.1-C.sub.9heteroaryl, C.sub.1-C.sub.6hydroxylalkyl-, C.sub.3-C.sub.10saturated or unsaturated mono or bicyclic C.sub.3-C.sub.10cycloalkyl optionally substituted with OH, NR.sup.11R.sup.11 or 3-7 membered C.sub.1-C.sub.6heterocyclyl, and 3-10 membered saturated or unsaturated mono or bicyclic C.sub.1-C.sub.9heterocyclyl, with the proviso that three-membered cycloalkyl and heterocyclyl rings are saturated; or two R.sup.5 groups taken together with the nitrogen atom to which they are attached form a 3 to 8 membered ring system optionally substituted with C.sub.1-C.sub.6alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from O, S, S(O), S(O).sub.2 and NR.sup.10; R.sup.10 is selected from the group consisting of H, C.sub.1-C.sub.6alkyl, --SO.sub.2(C.sub.1-C.sub.6alkyl), --COO(C.sub.1-C.sub.6alkyl), --CONH(C.sub.1-C.sub.6alkyl), --CON(C.sub.1-C.sub.6alkyl).sub.2, --CO(C.sub.1-C.sub.6alkyl), and --SO.sub.2NHR.sup.11; R.sup.11 is selected from the group consisting of H, C.sub.1-C.sub.6alkyl optionally substituted with OH, NR.sup.11R.sup.11 or a 3-7 membered C.sub.1-C.sub.6heterocyclyl, --CO(C.sub.1-C.sub.6alkyl), optionally substituted C.sub.6-C.sub.10aryl, and optionally substituted C.sub.1-C.sub.9heteroaryl; R.sup.4 is selected from the group consisting of: a) C.sub.1-C.sub.6alkyl optionally substituted with: i) 3-10 membered C.sub.1-C.sub.9heterocyclyl optionally substituted with C.sub.1-C.sub.6alkyl-, ii) H.sub.2N--, iii) (C.sub.1-C.sub.6alkyl)NH--, iv) (C.sub.1-C.sub.6alkyl).sub.2N--, v) NH(CH.sub.2).sub.aN(C.sub.1-C.sub.6alkyl).sub.2 wherein a is 2, 3 or 4, and vi) CHO, b) C.sub.3-C.sub.6alkenyl, c) C.sub.3-C.sub.6alkynyl, d) --O--C.sub.1-C.sub.8alkyl optionally substituted with --O--C.sub.1-C.sub.8alkyl, e) --O--C.sub.3-C.sub.8alkenyl, f) --O--C.sub.3-C.sub.8alkynyl, g) saturated or unsaturated mono or bicyclic C.sub.3-C.sub.8cycloalkyl, and h) saturated or unsaturated mono or bicyclic --O--C.sub.3-C.sub.12cycloalkyl, all the above optionally substituted with OH, NR.sup.11R.sup.11 or a 3-7 membered C.sub.1-C.sub.6heterocyclyl optionally substituted with C.sub.1-C.sub.6alkyl-, provided that an OH or NR.sup.11R.sup.11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; i) --CH.dbd.CH--C.sub.6-C.sub.10aryl; j) --CH.dbd.CH--C.sub.1-C.sub.9heteroaryl; k) optionally substituted C.sub.6-C.sub.10aryl; l) optionally substituted 5-10 membered C.sub.1-C.sub.9heteroaryl attached to the triazine moiety via a carbon atom; m) 3-10 membered saturated or unsaturated monocyclic C.sub.1-C.sub.9heterocyclyl attached to the triazine moiety through a carbon or nitrogen atom and optionally substituted with from 1 to 3 substituents independently selected from: OH, NR.sup.11R.sup.11, C.sub.1-C.sub.6alkyl, (C.sub.1-C.sub.6alkyl)amido-, (C.sub.1-C.sub.6alkyl)C(O)--, (C.sub.1-C.sub.6alkoxy)carbonyl-, adamantyl, C.sub.1-C.sub.6hydroxylalkyl-, (C.sub.1-C.sub.6alkyl)amido-; or a 3-7 membered C.sub.1-C.sub.6heterocyclyl, with the proviso that 3 membered heterocyclyl is saturated and attached to the triazine moiety through a nitrogen atom, and 5 membered bicyclic heterocyclyl is saturated; n) optionally substituted --O--C.sub.6-C.sub.10aryl; o) optionally substituted --O--C.sub.1-C.sub.9heteroaryl; p) --O-(3-12 membered saturated or unsaturated mono or bicyclic)C.sub.1-C.sub.9heterocyclyl optionally substituted with (C.sub.1-C.sub.6alkoxy)carbonyl-, H.sub.2NS(O).sub.2--, or C.sub.1-C.sub.6alkyl further optionally substituted with OH, NR.sup.11R.sup.11 or a 3-7 membered C.sub.1-C.sub.6heterocyclyl, with the proviso that three membered heterocyclyl is saturated; q) --NHC.sub.6-C.sub.10aryl, r) --NHC.sub.1-C.sub.9heteroaryl, s) --NHNH.sub.2, t) --NHNHC.sub.1-C.sub.6alkyl, u) --NHN(C.sub.1-C.sub.6alkyl).sub.2, v) --NHOH, w) --COOH, x) --COO--C.sub.1-C.sub.6alkyl, y) --CONR.sup.12R.sup.13, z) --NR.sup.12R.sup.13, ##STR00049## ##STR00050## ##STR00051## ##STR00052## wherein Z is CH.sub.2, O, S(O).sub.n or NR.sup.10 and n is 0, 1 or 2; ee) halogen, ff) C.sub.6-C.sub.14aryl-S(O).sub.2--NH--, gg) R.sup.11NHC(O)NH--O--, and hh) optionally substituted 5-membered monocyclic C.sub.1-C.sub.4heteroaryl attached to the triazine moiety via a nitrogen atom; R.sup.12 and R.sup.13 are each independently selected from H, optionally mono or disubstituted C.sub.1-C.sub.8alkyl, optionally substituted C.sub.3-C.sub.8alkenyl, and optionally substituted C.sub.3-C.sub.8alkynyl, the optional substituents being selected from C.sub.1-C.sub.6alkoxy, OH, NR.sup.11R.sup.11, and 3-7 membered C.sub.1-C.sub.6heterocyclyl, provided that an OH or NR.sup.11R.sup.11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; or R.sup.12 and R.sup.13 taken together with the nitrogen atom to which they are attached form a 3 to 8 membered monocyclic ring system optionally substituted with C.sub.1-C.sub.6alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from O, S(O).sub.n and NR.sup.10; ##STR00053## ##STR00054## ##STR00055## ##STR00056## or ##STR00057## or R.sup.12 and R.sup.13 taken together with the nitrogen atom to which they are attached form wherein a and b are each independently --CH.sub.2--, O, S, or NR.sup.10, and x is 1-3; C.sub.1-C.sub.9heteroaryl refers to a 5-10 membered aromatic ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from O, NR.sup.10, and S(O).sub.n; C.sub.1-C.sub.9heterocyclyl refers to a 3-10 membered ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from O, NR.sup.10, and S(O).sub.n; and optionally substituted aryl and heteroaryl groups are unsubstituted or are substituted with 1 or 2 moieties selected from the group consisting of: a) C.sub.1-C.sub.6alkyl optionally substituted with OH, NH.sub.2, NH(C.sub.1-C.sub.6alkyl), N(C.sub.1-C.sub.6alkyl).sub.2, --NH(CH.sub.2).sub.wN(C.sub.1-C.sub.6alkyl).sub.2 wherein w is 2, 3 or 4, or 3-10 membered C.sub.1-C.sub.9heterocyclyl optionally substituted with from 1 to 3 independently selected C.sub.1-C.sub.6alkyl- substituents; b) halogen; c) hydroxy; d) NH.sub.2; e) NO.sub.2; SO.sub.2NH.sub.2; g) COOH; h) COO(C.sub.1-C.sub.6alkyl); i) NHCOO(C.sub.1-C.sub.6alkyl); j) NH(C.sub.1-C.sub.6alkyl); k) N(C.sub.1-C.sub.6alkyl).sub.2; l) C(O)NR.sup.aR.sup.b, wherein R.sup.a is H or C.sub.1-C.sub.6alkyl, and R.sup.b is H, C.sub.1-C.sub.6alkyl, (C.sub.6-C.sub.14aryl)alkyl-, or (C.sub.1-C.sub.9heteroaryl)alkyl-; m) --Y-Q, wherein Y is: i) O, ii) NH, iii) N(C.sub.1-C.sub.6alkyl), iv) NHSO.sub.2, v) SO.sub.2NH, vi) NHCONH, vii) NHCON(C.sub.1-C.sub.6alkyl), viii) S(O).sub.q, q is 0, 1 or 2, ix) --C(O)NH--, x) --NHC(O)-- xi) --C(O)N(CH.sub.3)--, xii) C(O), or xiii) absent, and Q is selected from: i) C.sub.6-C.sub.10aryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C.sub.1-C.sub.6alkoxy- optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, 3) di(C.sub.1-C.sub.6alkyl)amino-, 4) C.sub.1-C.sub.9heterocyclyl- optionally substituted by C.sub.1-C.sub.6alkyl-, or 5) hydroxyl, B) (C.sub.1-C.sub.6alkoxy)carbonyl-, C) (C.sub.1-C.sub.6alkoxy)C(O)NH--, D) C.sub.1-C.sub.6alkyl- optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, or 3) di(C.sub.1-C.sub.6alkyl)amino-, E) (C.sub.1-C.sub.6alkyl)amino-, F) di(C.sub.1-C.sub.6alkyl)amino-, G) (C.sub.1-C.sub.6alkyl)amido- optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, or 3) di(C.sub.1-C.sub.6alkyl)amino-, H) (C.sub.1-C.sub.6alkyl)carboxyamido-, I) C.sub.1-C.sub.9heterocyclyl- optionally substituted by C.sub.1-C.sub.6alkyl- or C.sub.1-C.sub.6hydroxylalkyl-, J) heterocyclyl(C.sub.1-C.sub.6alkyl)- optionally substituted by C.sub.1-C.sub.6alkyl-, K) halogen, L) hydroxyl, M) C.sub.1-C.sub.6hydroxylalkyl-, N) perfluoro(C.sub.1-C.sub.6)alkyl-, O) H.sub.2N--, P) O.sub.2N--, Q) H.sub.2NSO.sub.2--, R) HO.sub.2C--, and S) NC--, ii) 5-10 membered C.sub.1-C.sub.9heteroaryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C.sub.1-C.sub.6alkoxy- optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, 3) di(C.sub.1-C.sub.6alkyl)amino-, 4) C.sub.1-C.sub.9heterocyclyl- optionally substituted by C.sub.1-C.sub.6alkyl-, or 5) hydroxyl, B) (C.sub.1-C.sub.6alkoxy)carbonyl-, C) (C.sub.1-C.sub.6alkoxy)C(O)NH--, D) C.sub.1-C.sub.6alkyl- optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, or 3) di(C.sub.1-C.sub.6alkyl)amino-, E) (C.sub.1-C.sub.6alkyl)amino-, F) di(C.sub.1-C.sub.6alkyl)amino-, G) (C.sub.1-C.sub.6alkyl)amido-optionally substituted with 1) H.sub.2N--, 2) (C.sub.1-C.sub.6alkyl)amino-, or 3) di(C.sub.1-C.sub.6alkyl)amino-, H) (C.sub.1-C.sub.6alkyl)carboxyamido-, I) C.sub.1-C.sub.9heterocyclyl- optionally substituted by C.sub.1-C.sub.6alkyl- or C.sub.1-C.sub.6hydroxylalkyl-, J) heterocyclyl(C.sub.1-C.sub.6alkyl)- optionally substituted by C.sub.1-C.sub.6alkyl-, K) halogen, L) hydroxyl, M) C.sub.1-C.sub.6hydroxylalkyl-, N) perfluoro(C.sub.1-C.sub.6)alkyl-, O) H.sub.2N--, P) O.sub.2N--, Q) H.sub.2NSO.sub.2--, R) HO.sub.2C--, and S) NC--, iii) 3-10 membered C.sub.1-C.sub.9heterocyclyl, optionally substituted with from 1 to 3 substituents independently selected from: A) C.sub.1-C.sub.6alkyl-, B) heterocyclyl(C.sub.1-C.sub.6alkyl)-, C) (C.sub.6-C.sub.14aryl)alkyl-, D) C.sub.1-C.sub.8acyl-, E) (C.sub.1-C.sub.6alkoxy)carbonyl-, F) (C.sub.1-C.sub.6alkyl)carboxyl-, G) halogen, H) C.sub.1-C.sub.6haloalkyl-, I) hydroxyl, J) C.sub.1-C.sub.6hydroxyalkyl-, K) H.sub.2N--, L) (C.sub.1-C.sub.6alkyl)amino-, M) di(C.sub.1-C.sub.6alkyl)amino-, N) HO.sub.2C--, O) (C.sub.1-C.sub.6alkoxy)carbonyl-, P) (C.sub.1-C.sub.6alkyl)carboxyl-, Q) (C.sub.1-C.sub.6alkyl)amido-, R) H.sub.2NC(O)--, S) (C.sub.1-C.sub.6alkyl)carboxyamido-, T) 5-10 membered C.sub.1-C.sub.9heteroaryl, U) C.sub.6-C.sub.14ary, V) C.sub.3-C.sub.8cycloalkyl W) 3-10 membered C.sub.1-C.sub.9heterocyclyl, X) NC--; and Y) --NO.sub.2; iv) C.sub.3-C.sub.10cycloalkyl, v) C.sub.1-C.sub.6alkyl, vi) C.sub.2-C.sub.6alkenyl, vii) C.sub.2-C.sub.6alkynyl, viii) C.sub.1-C.sub.6hydroxyalkyl-, ix) (CH.sub.2).sub.vO(C.sub.1-C.sub.6alkyl), x) (CH.sub.2).sub.vNH.sub.2, xi) (CH.sub.2).sub.vNH(C.sub.1-C.sub.6alkyl), xii) (CH.sub.2).sub.vN(C.sub.1-C.sub.6alkyl).sub.2, xiii) O(CH.sub.2).sub.vN(C.sub.1-C.sub.6alkyl).sub.2, xiv) (CH.sub.2).sub.vC.sub.6-C.sub.10aryl, xv) --CN, xvi) (CH.sub.2), 5-10 membered C.sub.1-C.sub.9heteroaryl, xvii) (CH.sub.2), 3-10 membered C.sub.1-C.sub.9heterocyclyl, optionally substituted by C.sub.1-C.sub.6alkyl-, wherein v is 1, 2, 3 or 4, and xviii) C.sub.1-C.sub.6 perfluoroalkyl-; and n) C(O)R.sup.c wherein R.sup.c is: i) H, ii) C.sub.1-C.sub.6alkyl, or iii) C.sub.3-C.sub.6cycloalkyl, or optionally a pharmaceutically acceptable salt thereof: and a second compound selected from the group consisting of: a topoisomerase I inhibitor, a MEK 1/2 inhibitor, a HSP90 inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, carmustine, lomustine, vinblastine, vincristine, vinorelbine, oxaliplatin, imatinib mesylate, bevacizumab, hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins, herbimycin A, genistein, erbstatin, hydroxyzine, glatiramer acetate, interferon beta-1a, interferon beta-1b, natalizumab and lavendustin A, or optionally a pharmaceutically acceptable salt thereof; in amounts effective to treat said cancer. 2. The method of claim 1 wherein R.sup.1 is ##STR00058## 3. The method of claim 1 wherein R.sup.2 is optionally substituted C.sub.6-C.sub.14aryl-NH--COR.sup.3. 4. The method of claim 1 wherein R.sup.2 is optionally substituted phenyl-NH--COR.sup.3. 5. The method of claim 1 wherein R.sup.3 is NHR.sup.5. 6. The method of claim 1, wherein said cancer is renal cell carcinoma. 7. The method of claim 1, wherein said cancer is acute lymphoblastic leukemia. 8. The method of claim 1, wherein said cancer is acute malignant melanoma. 9. A method of claim 1 wherein said cancer is soft-tissue or bone sarcoma. 10. A method of treating cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain cancer, soft-tissue sarcoma, and bone sarcoma, said method comprising concurrently administering to a mammal in need thereof a first compound: 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorph- olin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or optionally a pharmaceutically acceptable salt thereof; and a second compound selected from the group consisting of a topoisomerase I inhibitor, a MEK 1/2 inhibitor, a HSP90 inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, carmustine, lomustine, vinblastine, vincristine, vinorelbine, oxaliplatin, imatinib mesylate, bevacizumab, hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins, herbimycin A, genistein, erbstatin, hydroxyzine, glatiramer acetate, interferon beta-1a, interferon beta-1b, natalizumab and lavendustin A, or optionally a pharmaceutically acceptable salt thereof in an amount effective to treat the cancer. 11. The method of claim 1, wherein said second compound is a MEK 1/2 inhibitor. 12. The method of claim 10, wherein said compound is a MEK 1/2 inhibitor.

Details for Patent 8,859,542

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-05-23
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2028-05-23
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2028-05-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2028-05-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2028-05-23
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2028-05-23